Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.

Yuen, John G; Fesler, Andrew; Hwang, Ga-Ram; Chen, Lan-Bo; Ju, Jingfang

Yuen, John G; Fesler, Andrew; Hwang, Ga-Ram; Chen, Lan-Bo; Ju, Jingfang.

Afiliação

Yuen JG; Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Fesler A; Curamir Therapeutics Inc., Woburn, MA 01801, USA.
Hwang GR; Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Chen LB; Curamir Therapeutics Inc., Woburn, MA 01801, USA.
Ju J; Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Curamir Therapeutics Inc., Woburn, MA 01801, USA. Electronic address: jingfang.ju@stonybrookmedicine.edu.

Mol Ther ; 30(11): 3450-3461, 2022 11 02.

Article em En | MEDLINE | ID: mdl-35933584

Assuntos

MicroRNAs; Neoplasias Pancreáticas; Humanos; MicroRNAs/genética; MicroRNAs/metabolismo; Genes Supressores de Tumor; Fluoruracila/farmacologia; Neoplasias Pancreáticas/genética; Interferência de RNA; Regulação Neoplásica da Expressão Gênica

Palavras-chave

RNA delivery; breast cancer; cancer; colon cancer; gene therapy; lung cancer; microRNA; oligonucleotide-based therapies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / MicroRNAs Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google